APO RESEARCH · REPORT
Therapeutic Nuclear Medicines
Radioactive material, called radiopharmaceuticals, can be used to treat certain conditions. This is called nuclear medicine therapy.
Product & engineering
Understand the product.
Radioactive material, called radiopharmaceuticals, can be used to treat certain conditions. This is called nuclear medicine therapy.
Therapeutic nuclear medicines are a pharmaceutical formulation that consists of radioactive substances (radioisotopes). Therapeutic nuclear medicines are intending for the treatment of cancer, metastatic bone pain and other diseases. The radioactive material of therapeutic nuclear medicines is capable of killing the cancerous tissue, reducing the size of a tumor and reducing pain.
Selected research
Market Structure
Global Therapeutic Nuclear Medicines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Radioactive material, called radiopharmaceuticals, can be used to treat certain conditions. This is called nuclear medicine therapy.
Therapeutic nuclear medicines are a pharmaceutical formulation that consists of radioactive substances (radioisotopes). Therapeutic nuclear medicines are intending for the treatment of cancer, metastatic bone pain and other diseases. The radioactive material of therapeutic nuclear medicines is capable of killing the cancerous tissue, reducing the size of a tumor and reducing pain.
Global Therapeutic Nuclear Medicines key players include Bayer, Novartis AG, China Isotope & Radiation, etc. Global top three manufacturers hold a share over 75%.
Read the full market overview
North America is the largest market, with a share about 45%, followed by Europe and Asia-Pacific, both have a share about 50 percent.
In terms of product, Radium-223 is the largest segment, with a share over 45%. And in terms of application, the largest application is Thyroid, followed by Bone Metastasis.
This report provides an overview of the global Therapeutic Nuclear Medicines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Therapeutic Nuclear Medicines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Therapeutic Nuclear Medicines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Therapeutic Nuclear Medicines market size, projected growth trends, production technologies, key applications, and end-use industries.
Therapeutic Nuclear Medicines Segment by Company
Novartis AG
Bayer
China Isotope & Radiation
Q BioMed
Curium Pharmaceuticals
Jubilant DraxImage
Dongcheng
Lantheus
Acrotech Biopharma.
Progenics Pharmaceuticals
International Isotopes
Therapeutic Nuclear Medicines Segment by Type
Radium-223
Lutetium-177
Iodine-131
Other
Therapeutic Nuclear Medicines Segment by Application
Thyroid
Bone Metastasis
Lymphoma
Other
Therapeutic Nuclear Medicines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Nuclear Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Therapeutic Nuclear Medicines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Therapeutic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Therapeutic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Therapeutic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Radium-223
- Lutetium-177
- Iodine-131
- Other
Applications
- Thyroid
- Bone Metastasis
- Lymphoma
- Other
Companies covered
- Novartis AG
- Bayer
- China Isotope & Radiation
- Q BioMed
- Curium Pharmaceuticals
- Jubilant DraxImage
- Dongcheng
- Lantheus
- Acrotech Biopharma.
- Progenics Pharmaceuticals
- International Isotopes
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Therapeutic Nuclear Medicines Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Therapeutic Nuclear Medicines Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Therapeutic Nuclear Medicines Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Therapeutic Nuclear Medicines Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Therapeutic Nuclear Medicines Market Dynamics
- 2.1 Therapeutic Nuclear Medicines Industry Trends
- 2.2 Therapeutic Nuclear Medicines Industry Drivers
- 2.3 Therapeutic Nuclear Medicines Industry Opportunities and Challenges
- 2.4 Therapeutic Nuclear Medicines Industry Restraints
3 Therapeutic Nuclear Medicines Market by Manufacturers
- 3.1 Global Therapeutic Nuclear Medicines Revenue by Manufacturers (2021-2026)
- 3.2 Global Therapeutic Nuclear Medicines Sales by Manufacturers (2021-2026)
- 3.3 Global Therapeutic Nuclear Medicines Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Therapeutic Nuclear Medicines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Therapeutic Nuclear Medicines Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Therapeutic Nuclear Medicines Manufacturers, Product Type & Application
- 3.7 Global Therapeutic Nuclear Medicines Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Therapeutic Nuclear Medicines Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Therapeutic Nuclear Medicines Players Market Share by Revenue in 2025
- 3.8.3 2025 Therapeutic Nuclear Medicines Tier 1, Tier 2, and Tier 3
4 Therapeutic Nuclear Medicines Market by Type
- 4.1 Therapeutic Nuclear Medicines Type Introduction
- 4.1.1 Radium-223
- 4.1.2 Lutetium-177
- 4.1.3 Iodine-131
- 4.1.4 Other
- 4.2 Global Therapeutic Nuclear Medicines Sales by Type
- 4.2.1 Global Therapeutic Nuclear Medicines Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Therapeutic Nuclear Medicines Sales by Type (2021-2032)
- 4.2.3 Global Therapeutic Nuclear Medicines Sales Market Share by Type (2021-2032)
- 4.3 Global Therapeutic Nuclear Medicines Revenue by Type
- 4.3.1 Global Therapeutic Nuclear Medicines Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Therapeutic Nuclear Medicines Revenue by Type (2021-2032)
- 4.3.3 Global Therapeutic Nuclear Medicines Revenue Market Share by Type (2021-2032)
5 Therapeutic Nuclear Medicines Market by Application
- 5.1 Therapeutic Nuclear Medicines Application Introduction
- 5.1.1 Thyroid
- 5.1.2 Bone Metastasis
- 5.1.3 Lymphoma
- 5.1.4 Other
- 5.2 Global Therapeutic Nuclear Medicines Sales by Application
- 5.2.1 Global Therapeutic Nuclear Medicines Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Therapeutic Nuclear Medicines Sales by Application (2021-2032)
- 5.2.3 Global Therapeutic Nuclear Medicines Sales Market Share by Application (2021-2032)
- 5.3 Global Therapeutic Nuclear Medicines Revenue by Application
- 5.3.1 Global Therapeutic Nuclear Medicines Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Therapeutic Nuclear Medicines Revenue by Application (2021-2032)
- 5.3.3 Global Therapeutic Nuclear Medicines Revenue Market Share by Application (2021-2032)
6 Global Therapeutic Nuclear Medicines Sales by Region
- 6.1 Global Therapeutic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Therapeutic Nuclear Medicines Sales by Region (2021-2032)
- 6.2.1 Global Therapeutic Nuclear Medicines Sales by Region (2021-2026)
- 6.2.2 Global Therapeutic Nuclear Medicines Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Therapeutic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Therapeutic Nuclear Medicines Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Therapeutic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Therapeutic Nuclear Medicines Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Therapeutic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Therapeutic Nuclear Medicines Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Therapeutic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Therapeutic Nuclear Medicines Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Therapeutic Nuclear Medicines Revenue by Region
- 7.1 Global Therapeutic Nuclear Medicines Revenue by Region
- 7.1.1 Global Therapeutic Nuclear Medicines Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Therapeutic Nuclear Medicines Revenue by Region (2021-2026)
- 7.1.3 Global Therapeutic Nuclear Medicines Revenue by Region (2027-2032)
- 7.1.4 Global Therapeutic Nuclear Medicines Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Therapeutic Nuclear Medicines Revenue (2021-2032)
- 7.2.2 North America Therapeutic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Therapeutic Nuclear Medicines Revenue (2021-2032)
- 7.3.2 Europe Therapeutic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Therapeutic Nuclear Medicines Revenue (2021-2032)
- 7.4.2 Asia-Pacific Therapeutic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Therapeutic Nuclear Medicines Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Therapeutic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novartis AG
- 8.1.1 Novartis AG Company Information
- 8.1.2 Novartis AG Business Overview
- 8.1.3 Novartis AG Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novartis AG Therapeutic Nuclear Medicines Product Portfolio
- 8.1.5 Novartis AG Recent Developments
- 8.2 Bayer
- 8.2.1 Bayer Company Information
- 8.2.2 Bayer Business Overview
- 8.2.3 Bayer Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Bayer Therapeutic Nuclear Medicines Product Portfolio
- 8.2.5 Bayer Recent Developments
- 8.3 China Isotope & Radiation
- 8.3.1 China Isotope & Radiation Company Information
- 8.3.2 China Isotope & Radiation Business Overview
- 8.3.3 China Isotope & Radiation Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 China Isotope & Radiation Therapeutic Nuclear Medicines Product Portfolio
- 8.3.5 China Isotope & Radiation Recent Developments
- 8.4 Q BioMed
- 8.4.1 Q BioMed Company Information
- 8.4.2 Q BioMed Business Overview
- 8.4.3 Q BioMed Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Q BioMed Therapeutic Nuclear Medicines Product Portfolio
- 8.4.5 Q BioMed Recent Developments
- 8.5 Curium Pharmaceuticals
- 8.5.1 Curium Pharmaceuticals Company Information
- 8.5.2 Curium Pharmaceuticals Business Overview
- 8.5.3 Curium Pharmaceuticals Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Curium Pharmaceuticals Therapeutic Nuclear Medicines Product Portfolio
- 8.5.5 Curium Pharmaceuticals Recent Developments
- 8.6 Jubilant DraxImage
- 8.6.1 Jubilant DraxImage Company Information
- 8.6.2 Jubilant DraxImage Business Overview
- 8.6.3 Jubilant DraxImage Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Jubilant DraxImage Therapeutic Nuclear Medicines Product Portfolio
- 8.6.5 Jubilant DraxImage Recent Developments
- 8.7 Dongcheng
- 8.7.1 Dongcheng Company Information
- 8.7.2 Dongcheng Business Overview
- 8.7.3 Dongcheng Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Dongcheng Therapeutic Nuclear Medicines Product Portfolio
- 8.7.5 Dongcheng Recent Developments
- 8.8 Lantheus
- 8.8.1 Lantheus Company Information
- 8.8.2 Lantheus Business Overview
- 8.8.3 Lantheus Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Lantheus Therapeutic Nuclear Medicines Product Portfolio
- 8.8.5 Lantheus Recent Developments
- 8.9 Acrotech Biopharma.
- 8.9.1 Acrotech Biopharma. Company Information
- 8.9.2 Acrotech Biopharma. Business Overview
- 8.9.3 Acrotech Biopharma. Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Acrotech Biopharma. Therapeutic Nuclear Medicines Product Portfolio
- 8.9.5 Acrotech Biopharma. Recent Developments
- 8.10 Progenics Pharmaceuticals
- 8.10.1 Progenics Pharmaceuticals Company Information
- 8.10.2 Progenics Pharmaceuticals Business Overview
- 8.10.3 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Product Portfolio
- 8.10.5 Progenics Pharmaceuticals Recent Developments
- 8.11 International Isotopes
- 8.11.1 International Isotopes Company Information
- 8.11.2 International Isotopes Business Overview
- 8.11.3 International Isotopes Therapeutic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 International Isotopes Therapeutic Nuclear Medicines Product Portfolio
- 8.11.5 International Isotopes Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Therapeutic Nuclear Medicines Value Chain Analysis
- 9.1.1 Therapeutic Nuclear Medicines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Therapeutic Nuclear Medicines Production Mode & Process
- 9.2 Therapeutic Nuclear Medicines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Therapeutic Nuclear Medicines Distributors
- 9.2.3 Therapeutic Nuclear Medicines Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst